British Journal of Haematology最新文献

Identification of a GFI1B variant associated with abnormal platelet function and normal platelet count.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-23 DOI: 10.1111/bjh.19964

Nikesh Kawankar, Chandrakala Shanmukhaiah, Bipin Kulkarni

引用次数: 0

An editorial introduction: A vision for the future of haematology.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-22 DOI: 10.1111/bjh.19968

Andrew M Evens

引用次数: 0

Sickle cell anaemia therapy in 2025.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-22 DOI: 10.1111/bjh.19933

Alan N Schechter

引用次数: 0

Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-22 DOI: 10.1111/bjh.19959

Keith W Pratz

引用次数: 0

Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-22 DOI: 10.1111/bjh.19958

Ao Zhang, Zhenli Huang, Ran Zhang, Ruowen Wei, Shan Jiang, Hongru Chen, Xiena Cao, Wei Shi, Linghui Xia, Yu Hu

{"title":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.","authors":"Ao Zhang, Zhenli Huang, Ran Zhang, Ruowen Wei, Shan Jiang, Hongru Chen, Xiena Cao, Wei Shi, Linghui Xia, Yu Hu","doi":"10.1111/bjh.19958","DOIUrl":"https://doi.org/10.1111/bjh.19958","url":null,"abstract":"Acute graft-versus-host disease (aGVHD) significantly affects quality of life and outcomes in patients post-haploidentical haematopoietic stem cell transplantation (haplo-HSCT). Methotrexate (MTX) is commonly used to prevent aGVHD but can lead to complications like delayed haematological recovery and oral mucositis (OM). This study investigates the efficacy of anti-CD25 monoclonal antibody (mAb) as a potential MTX alternative. Participants were divided into two cohorts: a single-dose group (25 mg/day anti-CD25 mAb with MTX) and a double-dose group (50 mg/day anti-CD25 mAb without MTX). The primary end-point was the cumulative incidence (CI) of severe aGVHD by day 100. The double-dose cohort demonstrated a significantly lower CI of total aGVHD (23.53% vs. 42.11%, p = 0.009) and grade 3-4 aGVHD (7.35% vs. 18.42%, p = 0.047). After inverse probability of treatment weighting adjustment, the adjusted HR of double-dose compared with single-dose cohort for total aGVHD was 0.47 (95% CI 0.26-0.86; p = 0.015), 0.42(95% CI 0.15-1.22; p = 0.110) for grade III-IV aGVHD, 0.45 (95% CI 0.26-0.77; p = 0.004) for total cGVHD and 0.36 (95% CI 0.18-0.72; p = 0.004) for the moderate to severe cGVHD. Additionally, this double-dose regimen significantly reduced the incidence of oral mucositis and demonstrated lower rates of infections and haemorrhagic cystitis. These findings suggest that a double-dose anti-CD25 mAb regimen without MTX is a promising strategy for aGVHD prophylaxis in haplo-HSCT (ChiCTR2200060184).","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-22 DOI: 10.1111/bjh.19961

Federico Stella, Annalisa Chiappella, Martina Magni, Francesca Bonifazi, Chiara De Philippis, Maurizio Musso, Ilaria Cutini, Silva Ljevar, Anna Maria Barbui, Mirko Farina, Massimo Martino, Massimo Massaia, Giovanni Grillo, Piera Angelillo, Barbara Botto, Francesca Patriarca, Mauro Krampera, Luca Arcaini, Maria Chiara Tisi, Pierluigi Zinzani, Federica Sorà, Stefania Bramanti, Martina Pennisi, Cristiana Carniti, Paolo Corradini

{"title":"Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.","authors":"Federico Stella, Annalisa Chiappella, Martina Magni, Francesca Bonifazi, Chiara De Philippis, Maurizio Musso, Ilaria Cutini, Silva Ljevar, Anna Maria Barbui, Mirko Farina, Massimo Martino, Massimo Massaia, Giovanni Grillo, Piera Angelillo, Barbara Botto, Francesca Patriarca, Mauro Krampera, Luca Arcaini, Maria Chiara Tisi, Pierluigi Zinzani, Federica Sorà, Stefania Bramanti, Martina Pennisi, Cristiana Carniti, Paolo Corradini","doi":"10.1111/bjh.19961","DOIUrl":"https://doi.org/10.1111/bjh.19961","url":null,"abstract":"Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored in 61 of them. Clinical outcomes and toxicities are consistent with previous real-world evidence studies. Notably, beyond established poor prognostic factors-such as blastoid variant and elevated lactate dehydrogenase-Bruton tyrosine-kinase inhibitors (BTKi) refractoriness and platelet count emerged as significant predictors of survival. Specifically, the 1-year overall survival was 56% in BTKi-refractory patients compared to 92% in BTKi-relapsed patients (p = 0.0001). Our study also demonstrated that in-vivo monitoring of brexu-cel expansion is feasible and correlates with progression-free survival and toxicities. Progression-free survival at 1 year was 74% in patients categorized as strong expanders, based on brexu-cel peak concentration, versus 54% in poor expanders (p = 0.02). Furthermore, in-vivo expansion helped identify a high-risk group of non-responders, those with progressive or stable disease at the 90-day post-infusion evaluation (OR = 4.7, 95% CI = 1.1-34, p = 0.04) characterized by dismal outcomes. When integrated with other clinical factors, monitoring brexu-cel expansion could assist in recognizing patients at high risk of early relapse.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-19 DOI: 10.1111/bjh.19944

Stéphane De Botton, Christian Récher, Jorge Cortes, Antonio Curti, Pierre Fenaux, Pierre Peterlin, Arnaud Pigneux, Karen Yee, Andrew Wei, Alice Mims, Gary Schiller, Mwe Mwe Chao, Hua Tian, Justin M Watts

{"title":"Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.","authors":"Stéphane De Botton, Christian Récher, Jorge Cortes, Antonio Curti, Pierre Fenaux, Pierre Peterlin, Arnaud Pigneux, Karen Yee, Andrew Wei, Alice Mims, Gary Schiller, Mwe Mwe Chao, Hua Tian, Justin M Watts","doi":"10.1111/bjh.19944","DOIUrl":"https://doi.org/10.1111/bjh.19944","url":null,"abstract":"Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive to therapies compared to de novo AML. Olutasidenib, an oral small-molecule inhibitor of mutated IDH1 (mIDH1), showed encouraging and durable responses in a phase 1/2 study of adults with post-MPN mIDH1 AML. Patients received olutasidenib 150 mg BID monotherapy or in combination with azacitidine. Primary end-points: safety and best response defined as complete remission (CR), CR with partial haematological recovery or morphological leukaemia-free state (MLFS). Analysis included 15 patients with post-MPN mIDH1 AML; 10 had relapsed or refractory AML and five had newly diagnosed AML. Six were treated with olutasidenib monotherapy and nine in combination with azacitidine. Treatment emergent adverse events occurred in 15 patients, three of whom discontinued therapy. CR: 40% (n = 6/15); median duration of response: 15.6 months (range: 1.7-44.3); CR with incomplete haematological recovery: 13% (n = 2/15); MLFS: 7% (n = 1/15); composite complete remission (CRc): 53% (n = 8/15); and overall response rate (ORR): 60% (9/18). Median duration of CRc and ORR: 13.15 (range: 2.4-48.7) and 14.3 months (range: 2.4-48.7), respectively, and median overall survival: 13.8 months (95% confidence interval: 3.70-23.7). Olutasidenib demonstrated encouraging response rates with a manageable safety profile for patients with post-MPN mIDH1 AML.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142862636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-19 DOI: 10.1111/bjh.19962

Candace Frerich, Peng Li, Philipp W Raess, Jennifer Dunlap, Curtis Lachowiez, Jose Solis-Ruiz, Richard Press, Nicola Long, Ronan T Swords, Joanna Wiszniewska, Guang Fan, Wei Xie

引用次数: 0

Treating asymptomatic follicular lymphoma: What is the score?

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-18 DOI: 10.1111/bjh.19949

Ghassan Zammar, Chan Y Cheah

引用次数: 0

Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: A multicentre propensity score-matched study.

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-12-18 DOI: 10.1111/bjh.19940

Xi-Ran Hou, Zhen-Yu Yan, Shuang Liu, Na Gao, Jian Chen, Ya-Wen Wang, Liang Wang, Zhao Li, Xin-Ru Wang, Qiao-Feng Dong, Qiu-Yan Wang, Lin Sun, Yan-Ming Wang, Ji Ma, Ya-Jing Zhao, Zhi-Long Xu, Cong-Cong Cao, Jun Peng, Ming Hou, Xin-Guang Liu

{"title":"Corticosteroids plus metformin versus corticosteroids as front-line treatment for patients with newly diagnosed ITP and pre-existing type 2 diabetes mellitus: A multicentre propensity score-matched study.","authors":"Xi-Ran Hou, Zhen-Yu Yan, Shuang Liu, Na Gao, Jian Chen, Ya-Wen Wang, Liang Wang, Zhao Li, Xin-Ru Wang, Qiao-Feng Dong, Qiu-Yan Wang, Lin Sun, Yan-Ming Wang, Ji Ma, Ya-Jing Zhao, Zhi-Long Xu, Cong-Cong Cao, Jun Peng, Ming Hou, Xin-Guang Liu","doi":"10.1111/bjh.19940","DOIUrl":"https://doi.org/10.1111/bjh.19940","url":null,"abstract":"Corticosteroids are the standard first-line treatment for primary immune thrombocytopenia (ITP), with a high initial response but unsatisfactory sustained response (SR). Additionally, corticosteroids usually lead to hyperglycaemia especially in patients with pre-existing type 2 diabetes mellitus (T2DM). Besides reducing the blood glucose levels, metformin was found to have immunomodulatory effects. We hereby conducted a multicentre propensity score matching analysis of corticosteroids plus metformin versus corticosteroids for newly diagnosed ITP patients with pre-existing T2DM. After matching at a ratio of 1:1, there were 57 patients in each group. Baseline characteristics, comorbidities and other medications including concurrent hypoglycaemic medications were balanced between the two groups. No statistical difference was observed in the initial response rate at day 14. It was notable that patients in the metformin group had a significantly higher SR rate and longer duration of response compared to the non-metformin group. Metformin inclusion was associated with a higher incidence of stomach upset, which were generally tolerable. Our study provided evidence that the addition of metformin to corticosteroids might be a promising front-line treatment for newly diagnosed ITP patients with pre-existing T2DM.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142851710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0